159 related articles for article (PubMed ID: 10817524)
1. Synergistic effect of pramipexole and sertraline in the forced swimming test.
Maj J; Rogóz Z
Pol J Pharmacol; 1999; 51(6):471-5. PubMed ID: 10817524
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats.
Rogóz Z; Skuza G
Pharmacol Rep; 2006; 58(4):493-500. PubMed ID: 16963794
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant effects of pramipexole, a novel dopamine receptor agonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
J Neural Transm (Vienna); 1997; 104(4-5):525-33. PubMed ID: 9295183
[TBL] [Abstract][Full Text] [Related]
4. Is dopamine implicated in the antidepressant-like effects of selective serotonin reuptake inhibitors in the mouse forced swimming test?
Renard CE; Fiocco AJ; Clenet F; Hascoet M; Bourin M
Psychopharmacology (Berl); 2001 Dec; 159(1):42-50. PubMed ID: 11797068
[TBL] [Abstract][Full Text] [Related]
5. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test.
Redrobe JP; Bourin M
Psychopharmacology (Berl); 1998 Jul; 138(2):198-206. PubMed ID: 9718290
[TBL] [Abstract][Full Text] [Related]
6. Does combined treatment with novel antidepressants and a dopamine D3 receptor agonist reproduce cocaine discrimination in rats?
Filip M; Papla I
Pol J Pharmacol; 2001; 53(6):577-85. PubMed ID: 11985331
[TBL] [Abstract][Full Text] [Related]
7. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
[TBL] [Abstract][Full Text] [Related]
8. Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Berghauzen-Maciejewska K; Kuter K; Kolasiewicz W; Głowacka U; Dziubina A; Ossowska K; Wardas J
Behav Brain Res; 2014 Sep; 271():343-53. PubMed ID: 24956561
[TBL] [Abstract][Full Text] [Related]
9. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.
Siuciak JA; Fujiwara RA
Psychopharmacology (Berl); 2004 Sep; 175(2):163-9. PubMed ID: 14985923
[TBL] [Abstract][Full Text] [Related]
10. Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats.
Kitagawa K; Kitamura Y; Miyazaki T; Miyaoka J; Kawasaki H; Asanuma M; Sendo T; Gomita Y
Naunyn Schmiedebergs Arch Pharmacol; 2009 Jul; 380(1):59-66. PubMed ID: 19274453
[TBL] [Abstract][Full Text] [Related]
11. Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.
Takahashi E; Katayama M; Niimi K; Itakura C
Eur J Pharmacol; 2008 Jul; 589(1-3):149-56. PubMed ID: 18571641
[TBL] [Abstract][Full Text] [Related]
12. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression.
DeBattista C; Solvason HB; Breen JA; Schatzberg AF
J Clin Psychopharmacol; 2000 Apr; 20(2):274-5. PubMed ID: 10770475
[No Abstract] [Full Text] [Related]
13. Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice.
Da-Rocha MA; Puech AJ; Thiébot MH
J Psychopharmacol; 1997; 11(3):211-8. PubMed ID: 9305412
[TBL] [Abstract][Full Text] [Related]
14. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
[TBL] [Abstract][Full Text] [Related]
15. Treatment of depressive symptoms in Parkinson's disease.
Barone P
Eur J Neurol; 2011 Mar; 18 Suppl 1():11-5. PubMed ID: 21255198
[TBL] [Abstract][Full Text] [Related]
16. Increased sensitivity to antidepressants of D3 dopamine receptor-deficient mice in the forced swim test (FST).
Leggio GM; Micale V; Drago F
Eur Neuropsychopharmacol; 2008 Apr; 18(4):271-7. PubMed ID: 17804207
[TBL] [Abstract][Full Text] [Related]
17. The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat.
Daniel WA; Syrek M; Haduch A; Wójcikowski J
J Pharm Pharmacol; 2001 Apr; 53(4):449-61. PubMed ID: 11341361
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.
Corrigan MH; Denahan AQ; Wright CE; Ragual RJ; Evans DL
Depress Anxiety; 2000; 11(2):58-65. PubMed ID: 10812530
[TBL] [Abstract][Full Text] [Related]
19. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression.
Harkin A; Kelly JP; McNamara M; Connor TJ; Dredge K; Redmond A; Leonard BE
Eur J Pharmacol; 1999 Jan; 364(2-3):123-32. PubMed ID: 9932714
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine, but not sertraline or citalopram, potentiates the locomotor stimulant effect of cocaine: possible pharmacokinetic effects.
Fletcher PJ; Sinyard J; Salsali M; Baker GB
Psychopharmacology (Berl); 2004 Jul; 174(3):406-13. PubMed ID: 14740149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
